Original Article

Phenotypic and genotypic evaluation of aminoglycoside resistance in Escherichia coli isolated from patients with blood stream infections in Tehran, Iran

Abstract

Background and Objectives: Escherichia coli is a significant causative agent of bloodstream infections (BSIs). Aminoglycoside antibiotics play a crucial role in treating severe infections such as sepsis and pneumonia. However, resistance to these antibiotics often occurs due to the production of aminoglycoside-modifying enzymes (AMEs). This study was conducted to assess antimicrobial susceptibility patterns against various aminoglycosides and to determine the prevalence of common AME genes in E. coli strains isolated from BSIs.
Materials and Methods: Sixty-five E. coli isolates were obtained from blood samples in a referral hospital in Tehran, Iran. The susceptibility patterns of aminoglycosides were determined using disk diffusion method and AMEs genes were investigated using PCR assay.
Results: Resistance to aminoglycosides was observed in 64.6% (42/65) of the isolates. The most frequent resistance rate was found for kanamycin (44.6%) and gentamicin (38.5%), followed by tobramycin (29.2%) and amikacin (4.6%). The most frequent AME gene was aac(3)-IVa, which detected in 49.2% isolates, followed by aac(6)-Ib (40%), aac(3)-IIa (32.3%), and ant(2)-Ia (30.8%), respectively.
Conclusion: Athough the findings of this survey are based on specimens collected from a single hospital, our study shows that the high prevalence of aminoglycoside resistance is primarily attributed to the presence of the aac(3)-Iva, aac(6)-Ib and aac(3)-IIa genes. The low rate of resistance to amikacin makes this antibiotic a good candidate for treatment of BSIs due to E. coli.

1. Nagarjuna D, Dhanda RS, Gaind R, Yadav M. tcpC as a prospective new virulence marker in blood Escherichia coli isolates from sepsis patients admitted to the intensive care unit. New Microbes New Infect 2015; 7: 28-30.
2. Bou-Antoun S, Davies J, Guy R, Johnson AP, Sheridan EA, Hope RJ. Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014. Euro Surveill 2016; 21: 30329.
3. Mehl A, Åsvold BO, Lydersen S, Paulsen J, Solligård E, Damås JK, et al. Burden of bloodstream infection in an area of Mid-Norway 2002-2013: a prospective population-based observational study. BMC Infect Dis 2017; 17: 205.
4. Sawatwong P, Sapchookul P, Whistler T, Gregory CJ, Sangwichian O, Makprasert S, et al. High burden of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in older adults: A Seven-Year study in two rural thai provinces. Am J Trop Med Hyg 2019; 100: 943-951.
5. de Lastours V, Laouénan C, Royer G, Carbonnelle E, Lepeule R, Esposito-Farèse M, et al. Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it. J Antimicrob Chemother 2020; 75: 2334-2343.
6. Naylor NR, Pouwels KB, Hope R, Green N, Henderson KL, Knight GM, et al. The health and cost burden of antibiotic resistant and susceptible Escherichia coli bacteraemia in the English hospital setting: A national retrospective cohort study. PLoS One 2019; 14(9): e0221944.
7. Thy M, Timsit J-F, de Montmollin E. Aminoglycosides for the treatment of severe infection due to resistant Gram-negative pathogens. Antibiotics (Basel) 2023; 12: 860.
8. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010; 13: 151-171.
9. Zhang X, Li Q, Lin H, Zhou W, Qian C, Sun Z, et al. High-Level aminoglycoside resistance in human clinical Klebsiella pneumoniae complex isolates and characteristics of armA-Carrying IncHI5 Plasmids. Front Microbiol 2021; 12: 636396.
10. Becker B, Cooper MA. Aminoglycoside antibiotics in the 21st century. ACS Chem Biol 2013; 8: 105-115.
11. Algarni S, Ricke SC, Foley SL, Han J. The Dynamics of the antimicrobial resistance mobilome of Salmonella enterica and related enteric bacteria. Front Microbiol 2022; 13: 859854.
12. Kirn TJ, Weinstein MP. Update on blood cultures: how to obtain, process, report, and interpret. Clin Microbiol Infect 2013; 19: 513-520.
13. Queipo-Ortuño MI, De Dios Colmenero J, Macias M, Bravo MJ, Morata P. Preparation of bacterial DNA template by boiling and effect of immunoglobulin G as an inhibitor in real-time PCR for serum samples from patients with brucellosis. Clin Vaccine Immunol 2008; 15: 293-296.
14. Fernández-Martínez M, Ruiz Del Castillo B, Lecea-Cuello MJ, Rodríguez-Baño J, Pascual Á, Martínez-Martínez L. Prevalence of Aminoglycoside-Modifying enzymes in Escherichia coli and Klebsiella pneumoniae producing extended spectrum β-Lactamases collected in two multicenter studies in Spain. Microb Drug Resist 2018; 24: 367-376.
15. Soleimani N, Aganj M, Ali L, Shokoohizadeh L, Sakinc T. Frequency distribution of genes encoding aminoglycoside modifying enzymes in uropathogenic E. coli isolated from Iranian hospital. BMC Res Notes 2014; 7: 842.
16. Fernández-Martínez M, Miró E, Ortega A, Bou G, González-López JJ, Oliver A, et al. Molecular identification of aminoglycoside-modifying enzymes in clinical isolates of Escherichia coli resistant to amoxicillin/clavulanic acid isolated in Spain. Int J Antimicrob Agents 2015; 46: 157-163.
17. Mir AR, Bashir Y, Dar FA, Sekhar M. Identification of genes coding aminoglycoside modifying enzymes in E. coli of UTI patients in India. ScientificWorldJournal 2016; 2016: 1875865.
18. Ojdana D, Sieńko A, Sacha P, Majewski P, Wieczorek P, Wieczorek A, et al. Genetic basis of enzymatic resistance of E. coli to aminoglycosides. Adv Med Sci 2018; 63: 9-13.
19. Gad GF, Mohamed HA, Ashour HM. Aminoglycoside resistance rates, phenotypes, and mechanisms of Gram-negative bacteria from infected patients in upper Egypt. PLoS One 2011; 6(2): e17224.
20. Kotra LP, Haddad J, Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 2000; 44: 3249-3256.
21. Sadeghi M, Mojtahedi A, Sedigh H, Nikokar I, Roushan ZA. Genetic diversity and prevalence of aminoglycoside modifying enzymes among Escherichia coli strains isolated from inpatients with urinary tract infections. Gene Rep 2020; 21: 100957.
22. Ghotaslou R, Yeganeh Sefidan F, Akhi MT, Asgharzadeh M, Mohammadzadeh Asl Y. Dissemination of genes encoding aminoglycoside-modifying enzymes and armA among Enterobacteriaceae isolates in northwest Iran. Microb Drug Resist 2017; 23: 826-832.
Files
IssueVol 16 No 2 (2024) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v16i2.15351
Keywords
Aminoglycoside resistance; Escherichia coli; Bacteremia; Aminoglycoside-modifying enzymes
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ghamari M, Emaneini M, Hemmati S, Jabalameli F, Beigverdi R. Phenotypic and genotypic evaluation of aminoglycoside resistance in Escherichia coli isolated from patients with blood stream infections in Tehran, Iran. Iran J Microbiol. 2024;16(2):187-192.